Dupixent is an injectable biologic medicine. Here’s how it helps COPD.

Dupixent becomes the first FDA-approved biologic drug for treating uncontrolled COPD, offering new hope for patients with this chronic respiratory condition.

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Dupixent®, or dupilumab, was the first biologic medicine approved for COPD in the U.S., and targets IL-4 and IL-13 signaling, which are two of the key immune molecules involved in a type 2 ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The FDA has approved Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype.

Learn about side effects, cost, and more of Dupixent (dupilumab). It’s a prescription drug that treats atopic dermatitis (a type of eczema) and other conditions.

The FDA has expanded the label of Regeneron and Sanofi's Dupixent to treat COPD. Dupixent becomes the first biologic for COPD patients in the U.S.